Medical Device News Magazine

Pneuma Systems Names Dr Roxie Mooney, Global Leader in Healthcare Innovation Strategy, as Director

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Pneuma Systems Corporation (Pneuma), an emerging leader in the infusion therapy industry, today announced the appointment of Roxie Mooney, DBA to its Board of Directors. The company is appointing Dr. Mooney as it commercializes infusion innovations in a $20-billion infusion therapy market forecast to top $31 billion by 2030[1]. Pneuma is launching innovative solutions that will provide a seamless continuum of care for patients facing a complex array of infusion therapies.

Dr Roxie Mooney complements vast experiences in medical product development and manufacturing from Pneuma’s Board, including CEO Jeffrey Carlisle, Minivalve International (Netherlands) CEO Peter Nijland, and Scott Young, PhD, VP Venture & External Collaboration at West Pharmaceuticals. Dr. Mooney is a world-recognized expert in the science of disruptive technologies in healthcare. As the CEO of Legacy DNA and proponent of the works of the late Harvard Business School professor, author, and innovation pioneer Clayton Christensen, she has guided many emerging companies through the complex challenges of commercializing healthcare innovations. Dr. Mooney is the author of the Amazon #1 international best-selling book How Health Innovators Maximize Market Success, executive producer and host of The Health Innovators Podcast and Video Show, and a highly sought-after speaker at major industry events.

Transforming Infusion Care

Historically, infusion pump companies have failed to meet the dynamic set of clinical requirements throughout a patient’s infusion therapy journey. Pneuma is simplifying this journey with a series of integrated solutions for the delivery of intravenous fluids.

“Most companies say that they’re doing things that have never been done before. But once you look under the hood, you find they’re not necessarily doing anything to disrupt or innovate healthcare,” explained Dr. Mooney. “Pneuma is different. They’re truly disrupting the healthcare status quo by making infusion care easier and safer for patients and nurses.”

“Dr. Mooney adds vital skills to our Board,” said Pneuma CEO Jeffrey Carlisle. “We need an experienced guide as we introduce unprecedented innovation to one of the most important and prevalent procedures in healthcare. While our team has experience with dozens of innovations, Dr. Mooney has been involved with hundreds.”

“Commercializing a true healthcare innovation is incredibly complex. But we need a bold champion in healthcare that changes lives,” added Dr. Mooney. “Pneuma is that champion, with products and services that hold significant promise for enhanced infusion patient therapies and outcomes in the near future.”

Dr. Mooney holds a Doctor of Business Administration degree from Walden University with post-graduate studies at Harvard Business School.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”